Clinical Trials for Esophageal Cancer

A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open-label multicohort study for patients with CLDN18.2-expressing unresectable locally advanced or metastatic gastroesophageal adenocarcinoma, pancreatic adenocarcinoma, or selected other solid tumors after at least one prior systemic therapy and ECOG 0–1. Participants receive IV ASP546C every 3 weeks, a CLDN18.2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload, with dose evaluation in gastroesophageal cancer and higher-dose cohorts in pancreatic and pan-tumor populations.

ClinicalTrials.gov ID: NCT07488676

A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants With Advanced Gastrointestinal Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic esophageal, gastroesophageal junction, gastric, or colorectal adenocarcinoma with measurable disease and ECOG 0–1 receive DISP-10, combining DV-10 adenoviral therapy with BCMA-directed autologous CAR T-cell therapy idecabtagene vicleucel after fludarabine/cyclophosphamide lymphodepletion. The study includes dose escalation and expansion to assess safety and preliminary antitumor activity in GI solid tumors.

ClinicalTrials.gov ID: NCT07544589

A Phase 1b/II Study of Intratumoral CD40 Agonist 2141-V11 in Combination With Anti PD-1 and 5-Fluorouracil Therapy in Patients With Advanced Gastroesophageal Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma are eligible if they have had 3–9 months of first-line fluoropyrimidine plus anti-PD-1 therapy without progression and have an endoscopically accessible primary tumor. Treatment adds intratumoral 2141-V11, an Fc-engineered CD40 agonist antibody, to nivolumab with a fluoropyrimidine (mandatory in the safety lead-in).

ClinicalTrials.gov ID: NCT07818018

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with incurable locally advanced or metastatic epithelial solid tumors, particularly NSCLC, who have measurable disease and ECOG performance status 0–1. Patients receive intravenous BL-B01D1 (izalontamab brengitecan), an investigational EGFR/HER3-targeting bispecific antibody–drug conjugate that delivers a topoisomerase I inhibitor, on one of two 21-day dosing schedules.

ClinicalTrials.gov ID: NCT05983432

A Phase 1/2, Open-label, Dose-escalation, and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101 As a Single Agent and in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients with Advanced or Metastatic Solid Tumors (Keynote B59)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, measurable disease, and ECOG performance status 0–1 receive GI-101 or GI-101A alone or in combination with pembrolizumab; GI-101 may also be combined with lenvatinib or local radiotherapy. GI-101 is a CD80–IL-2-variant fusion protein designed to counter CTLA-4-mediated suppression and stimulate cytotoxic T and natural-killer cells; GI-101A is a manufacturing-optimized formulation.

ClinicalTrials.gov ID: NCT04977453

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls patients with unresectable locally advanced or metastatic solid tumors who have exhausted, cannot tolerate, or are ineligible for standard therapy, with expansion cohorts focused on melanoma, renal cell carcinoma, and selected NSCLC. Patients receive imneskibart (AU-007), an anti-IL-2 antibody that blocks IL-2 binding to CD25, alone or with aldesleukin; some cohorts also receive avelumab or nivolumab.

ClinicalTrials.gov ID: NCT05267626

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with measurable metastatic or unresectable solid tumors and ECOG 0–1, including previously treated patients in monotherapy cohorts and treatment-naive patients with advanced NSCLC, head and neck, or esophageal cancer in combination cohorts. Patients receive sigvotatug vedotin, an integrin β6–targeting antibody–drug conjugate that delivers the microtubule-disrupting payload MMAE, alone or with pembrolizumab, with or without platinum chemotherapy.

ClinicalTrials.gov ID: NCT04389632

A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable solid tumors and ECOG 0–1 receive PF-08046054, a PD-L1-targeted antibody–drug conjugate that delivers the microtubule inhibitor MMAE, alone or with the PD-1 inhibitor pembrolizumab. Combination cohorts are limited to PD-L1-positive NSCLC or head and neck squamous cell carcinoma.

ClinicalTrials.gov ID: NCT05208762

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and refractory advanced solid tumors are eligible for dose escalation; expansion focuses on unresectable or metastatic NSCLC or HNSCC previously treated with platinum chemotherapy and PD-1/PD-L1 blockade, excluding NSCLC with known EGFR mutations or ALK rearrangements. Patients receive intravenous ABBV-514, an investigational anti-CCR8 antibody designed to deplete tumor-infiltrating regulatory T cells, alone or with budigalimab, an investigational anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT05005403

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with previously treated, locally advanced or metastatic, HER2 IHC 3+ solid tumors (excluding biliary tract cancers) who have progressed after at least one prior systemic therapy and lack standard treatment options; patients receive zanidatamab, a bispecific antibody targeting two HER2 epitopes. Eligible patients must have measurable disease, ECOG 0–1, and no active CNS metastases.

ClinicalTrials.gov ID: NCT06695845